Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY2880070 |
| Synonyms | |
| Therapy Description |
LY2880070 selectively inhibits CHK1, which potentially results in increased response to chemotherapeutic agents (PMID: 28331049). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY2880070 | ESP-01|LY 2880070|LY-2880070 | CHK1 Inhibitor 18 | LY2880070 selectively inhibits CHK1, which potentially results in increased response to chemotherapeutic agents (PMID: 28331049). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Completed | USA | POL | HRV | CAN | 0 |